Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chewell is a preclinical-stage small molecule cannabinoid composition developed by APIRx Pharma Sciences. The active ingredient is tetrahydrocannabivarin (THCV), a naturally occurring cannabinoid that interacts with the endocannabinoid system by targeting the CB1 and CB2 receptors. Unlike THC, THCV is often characterized as a CB1 receptor antagonist, which has led to research into its potential for metabolic and neurological applications. Chewell is currently part of APIRx's intellectual property portfolio with patent applications pending. The name suggests a formulation potentially designed for oral or buccal delivery, such as a medicated chewing gum, which aligns with the developer's specialized delivery platform technologies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chewell.